Compare NOMA & FLNA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | NOMA | FLNA |
|---|---|---|
| Founded | 2023 | 1998 |
| Country | United States | United States |
| Employees | 8 | 20 |
| Industry | Services-Misc. Amusement & Recreation | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.4M | 61.8M |
| IPO Year | N/A | N/A |
| Metric | NOMA | FLNA |
|---|---|---|
| Price | $3.38 | $1.24 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 7.8K | ★ 352.7K |
| Earning Date | 05-22-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $2.55 | $1.16 |
| 52 Week High | $10.00 | $2.03 |
| Indicator | NOMA | FLNA |
|---|---|---|
| Relative Strength Index (RSI) | 51.00 | 38.93 |
| Support Level | $3.30 | $1.16 |
| Resistance Level | $3.90 | $1.80 |
| Average True Range (ATR) | 0.26 | 0.09 |
| MACD | 0.01 | -0.01 |
| Stochastic Oscillator | 59.09 | 14.00 |
Nomadar Corp operates at the intersection of sports and technology, focusing on high-performance training programs and cultural exchange. The company aims to connect athletes, coaches, and fans through inventive technological solutions, enhancing sports development beyond physical borders. It offers services like the High Performance Training (HPT) program and promotes the legacy of iconic athletes. The Company generates revenue through its High Performance Training Program and events management at the JP Financial Stadium.
Filana Therapeutics Inc is a biotechnology company focused on developing novel, investigational therapies to modulate the filamin A protein for the treatment of central nervous system disorders, such as tuberous sclerosis complex (TSC)-related epilepsy, and other diseases associated with dysregulation or overexpression of filamin A. Its therapeutic product candidate, simufilam, is a proprietary small molecule oral treatment drug being studied for the treatment of TSC-related epilepsy.